<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600715</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003056</org_study_id>
    <secondary_id>15-051</secondary_id>
    <nct_id>NCT02600715</nct_id>
  </id_info>
  <brief_title>Reduction of Bladder Injection Pain With Belladonna Opiate Suppository</brief_title>
  <acronym>ROBIN</acronym>
  <official_title>Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edgar LeClaire, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether using belladonna &amp; opiate suppositories (B&amp;Os)
      can improve patient discomfort during Onabotulinumtoxin A (BoNT) injection into the bladder
      for treatment of overactive bladder, neurogenic detrusor overactivity, or interstitial
      cystitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 26, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bladder Injection Pain</measure>
    <time_frame>Baseline and intraoperative</time_frame>
    <description>The primary outcome will be calculated difference in numeric rating scale (NRS) pain score prior to procedure and midway through procedure. Scale is one question and has a range from a score of 0 (no pain) to 10 (worst possible pain). Measure will be reported as the intraoperative pain score minus the preoperative pain score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-analgesia Pain Score</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using NRS. Scale is one question and has a range from a score of 0 (no pain) to 10 (worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Pain Score</measure>
    <time_frame>Postoperative (within 10 minutes of the end of the BoNT procedure)</time_frame>
    <description>Measured using NRS. Scale is one question and has a range from a score of 0 (no pain) to 10 (worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Declining to Complete Procedure Due to Pain Intolerance</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Number of patients that decline to proceed with entire procedure (20 injections) due to pain or discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Voiding Trial Results</measure>
    <time_frame>Postoperative (before leaving the clinic, within 3 hours of the end of the BoNT procedure)</time_frame>
    <description>Distribution of patients with postoperative volume in ml of post-void residual urine obtained via catheter greater than 200ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Void Residual (PVR)</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Distribution of patients with volume in ml of post-void residual urine obtained via catheter greater than 200 ml at 2-week follow-up appointment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Evidence of Infection or Positive Urine Culture</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Urinalysis results showing evidence of infection or positive urine culture at 2-week follow-up appointment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction With Pain Control</measure>
    <time_frame>Postoperative (within 10 minutes of the end of the BoNT procedure)</time_frame>
    <description>Measured using one question Likert scale. This will be a 4-level scale ranging from 'not at all satisfied,' 'slightly satisfied,' 'mostly satisfied,' and 'very much satisfied.'</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Urge Incontinence</condition>
  <condition>Urinary Bladder, Neurogenic</condition>
  <condition>Painful Bladder Syndrome</condition>
  <arm_group>
    <arm_group_label>Active B&amp;O suppository of belladonna</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo suppository</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onabotulinumtoxin A (BoNT)</intervention_name>
    <arm_group_label>Active B&amp;O suppository of belladonna</arm_group_label>
    <arm_group_label>Placebo suppository</arm_group_label>
    <other_name>Botox</other_name>
    <other_name>Allergan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>belladonna</intervention_name>
    <description>Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.</description>
    <arm_group_label>Active B&amp;O suppository of belladonna</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.</description>
    <arm_group_label>Active B&amp;O suppository of belladonna</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo to B&amp;O suppository</description>
    <arm_group_label>Placebo suppository</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active B&amp;O suppository of belladonna</intervention_name>
    <description>belladonna 16.2mg and morphine 7.5mg</description>
    <arm_group_label>Active B&amp;O suppository of belladonna</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Met clinical criteria under outside care or during the Principal Investigator's
             routine standard of care for BoNT injection therapy

          -  No contraindication to BoNT therapy as outlined by drug manufacturer guidelines

          -  Participants have elected to have the BoNT injection therapy prior to being offered
             enrollment into the study for either overactive bladder (OAB), neurogenic detrusor
             overactivity (NDO), or refractory interstitial cystitis (IC)

        Exclusion Criteria:

          -  Currently pregnant

          -  Currently nursing a baby

          -  Anticipated geographic relocation within the first 3 months following treatment

          -  Allergy to morphine, belladonna, or opiates

          -  Patients will be excluded if participating in another research study

          -  Individuals unable to provide informed consent or to complete two-week follow-up
             bladder testing (post-void residual) or data collection will also be excluded
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edgar LeClaire, MD, FACOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wichita Women's Pelvic Surgery Center at Associates in Women's Health</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas School of Medicine - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <results_first_submitted>June 26, 2018</results_first_submitted>
  <results_first_submitted_qc>August 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2018</results_first_posted>
  <last_update_submitted>August 24, 2018</last_update_submitted>
  <last_update_submitted_qc>August 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Edgar LeClaire, MD</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 5, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02600715/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02600715/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began December 1, 2015 at a private urogynecology clinic. There were 32 patients that were assessed for eligibility. Four patients were excluded: three patients did not meet inclusion criteria (did not proceed with in-office treatment) and one patient declined to participate due to wanting the active suppository.</recruitment_details>
      <pre_assignment_details>28 patients consented to participate in the study. Two patients withdrew consent to participate and did not end up participating: one patient's medication resumed efficacy, and one patient withdrew regarding possible use of narcotics and concern due to a a previous narcotic addition.
Thus, only 26 patients are considered enrolled in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Belladonna &amp; Opiate (B&amp;O) Suppository</title>
          <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
        </group>
        <group group_id="P2">
          <title>Placebo Suppository</title>
          <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Allocated to Randomization</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment and Suppository</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 2-week Follow-up Appointment</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active B&amp;O Suppository of Belladonna</title>
          <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo Suppository</title>
          <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.62" spread="10.25"/>
                    <measurement group_id="B2" value="65.54" spread="10.22"/>
                    <measurement group_id="B3" value="69.58" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.45" spread="11.34"/>
                    <measurement group_id="B2" value="34.19" spread="6.33"/>
                    <measurement group_id="B3" value="34.82" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vaginal parity</title>
          <description>Vaginal parity is the number of pregnancies that the patient had, that was carried to greater 20 weeks.
Zero indicates that the patient did not have any pregnancies beyond 20 weeks (nulliparous).</description>
          <units>pregnancies</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B2" value="3" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B3" value="2" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estrogen use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Vaginal estrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral estrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gynecologic disorders/diagnoses</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Vulvovaginal atrophy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic cystitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cystocele</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal vault prolapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine prolapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectocele</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medication use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Steroid medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Narcotic medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretic medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hysterectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilateral salpingo-oophorectomy (BSO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolapse surgery with mesh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolapse surgery without mesh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous sling procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laparotomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back or spinal surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medication use in Last 24 Hours</title>
          <description>Participant medication use in last 24 hours prior to intravesical onabotulinum toxin A injection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Selective serotonin reuptake inhibitors (SSRIs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonsteroidal anti-inflammatory drugs (NSAIDs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sedative medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuromodulator medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opioid medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Bladder Injection Pain</title>
        <description>The primary outcome will be calculated difference in numeric rating scale (NRS) pain score prior to procedure and midway through procedure. Scale is one question and has a range from a score of 0 (no pain) to 10 (worst possible pain). Measure will be reported as the intraoperative pain score minus the preoperative pain score.</description>
        <time_frame>Baseline and intraoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active B&amp;O Suppository of Belladonna</title>
            <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>26 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bladder Injection Pain</title>
          <description>The primary outcome will be calculated difference in numeric rating scale (NRS) pain score prior to procedure and midway through procedure. Scale is one question and has a range from a score of 0 (no pain) to 10 (worst possible pain). Measure will be reported as the intraoperative pain score minus the preoperative pain score.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Test for differences in continuous variables.</non_inferiority_desc>
            <p_value>0.94</p_value>
            <p_value_desc>Two-sided alpha of 0.05 was used to determine statistical significance.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-analgesia Pain Score</title>
        <description>Measured using NRS. Scale is one question and has a range from a score of 0 (no pain) to 10 (worst possible pain).</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active B&amp;O Suppository of Belladonna</title>
            <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>26 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-analgesia Pain Score</title>
          <description>Measured using NRS. Scale is one question and has a range from a score of 0 (no pain) to 10 (worst possible pain).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Pain Score</title>
        <description>Measured using NRS. Scale is one question and has a range from a score of 0 (no pain) to 10 (worst possible pain).</description>
        <time_frame>Postoperative (within 10 minutes of the end of the BoNT procedure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active B&amp;O Suppository of Belladonna</title>
            <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>26 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain Score</title>
          <description>Measured using NRS. Scale is one question and has a range from a score of 0 (no pain) to 10 (worst possible pain).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Declining to Complete Procedure Due to Pain Intolerance</title>
        <description>Number of patients that decline to proceed with entire procedure (20 injections) due to pain or discomfort.</description>
        <time_frame>Intraoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active B&amp;O Suppository of Belladonna</title>
            <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>26 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Declining to Complete Procedure Due to Pain Intolerance</title>
          <description>Number of patients that decline to proceed with entire procedure (20 injections) due to pain or discomfort.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Voiding Trial Results</title>
        <description>Distribution of patients with postoperative volume in ml of post-void residual urine obtained via catheter greater than 200ml.</description>
        <time_frame>Postoperative (before leaving the clinic, within 3 hours of the end of the BoNT procedure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active B&amp;O Suppository of Belladonna</title>
            <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>26 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Voiding Trial Results</title>
          <description>Distribution of patients with postoperative volume in ml of post-void residual urine obtained via catheter greater than 200ml.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Void Residual (PVR)</title>
        <description>Distribution of patients with volume in ml of post-void residual urine obtained via catheter greater than 200 ml at 2-week follow-up appointment.</description>
        <time_frame>2 Weeks</time_frame>
        <population>One patient did not complete 2-week follow-up post-void residual exam.</population>
        <group_list>
          <group group_id="O1">
            <title>Active B&amp;O Suppository of Belladonna</title>
            <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>25 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Post Void Residual (PVR)</title>
          <description>Distribution of patients with volume in ml of post-void residual urine obtained via catheter greater than 200 ml at 2-week follow-up appointment.</description>
          <population>One patient did not complete 2-week follow-up post-void residual exam.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Evidence of Infection or Positive Urine Culture</title>
        <description>Urinalysis results showing evidence of infection or positive urine culture at 2-week follow-up appointment.</description>
        <time_frame>2 Weeks</time_frame>
        <population>One patient did not complete 2-week follow-up appointment.</population>
        <group_list>
          <group group_id="O1">
            <title>Active B&amp;O Suppository of Belladonna</title>
            <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>25 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Evidence of Infection or Positive Urine Culture</title>
          <description>Urinalysis results showing evidence of infection or positive urine culture at 2-week follow-up appointment.</description>
          <population>One patient did not complete 2-week follow-up appointment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Satisfaction With Pain Control</title>
        <description>Measured using one question Likert scale. This will be a 4-level scale ranging from 'not at all satisfied,' 'slightly satisfied,' 'mostly satisfied,' and 'very much satisfied.'</description>
        <time_frame>Postoperative (within 10 minutes of the end of the BoNT procedure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active B&amp;O Suppository of Belladonna</title>
            <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suppository</title>
            <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>26 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Satisfaction With Pain Control</title>
          <description>Measured using one question Likert scale. This will be a 4-level scale ranging from 'not at all satisfied,' 'slightly satisfied,' 'mostly satisfied,' and 'very much satisfied.'</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mostly satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two-weeks</time_frame>
      <desc>Adverse event reporting is applicable to only participants that completed the two week follow-up visit post-operative. Thus, only 25 participants are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active B&amp;O Suppository of Belladonna</title>
          <description>Receive the B&amp;O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
belladonna: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Morphine: Part of dosage of the compounded active B&amp;O suppository of belladonna 16.2mg and morphine 7.5mg.
Active B&amp;O suppository of belladonna: belladonna 16.2mg and morphine 7.5mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo Suppository</title>
          <description>Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
Onabotulinumtoxin A (BoNT)
Placebo: matching placebo to B&amp;O suppository</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>25 participants completed the two-week follow-up visit</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection Two Weeks Post-operative</sub_title>
                <description>At the two week follow-up appointment, when indicated, specimens were sent for confirmatory culture if urinalysis indicated infection and empiric antibiotic treatment was initiated.</description>
                <counts group_id="E1" events="13" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="25" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Duong, MPH, Research Associate</name_or_title>
      <organization>University of Kansas School of Medicine-Wichita</organization>
      <phone>316-962-3126</phone>
      <email>jduong@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

